MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.00% | 6.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.00% | 40.99% | |||
| Operating Income | -15.00% | -40.99% | |||
| Income Before Tax | -28.68% | -45.96% | |||
| Income Tax Expenses | -55.37% | 17.03% | |||
| Earnings from Continuing Operations | -28.47% | -45.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 9.27% | 47.26% | |||
| Net Income | -28.86% | -45.84% | |||
| EBIT | -15.00% | -40.99% | |||
| EBITDA | -12.07% | -41.01% | |||
| EPS Basic | -28.51% | -45.78% | |||
| Normalized Basic EPS | -28.98% | -45.85% | |||
| EPS Diluted | -28.51% | -45.78% | |||
| Normalized Diluted EPS | -28.98% | -45.85% | |||
| Average Basic Shares Outstanding | 0.28% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.28% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
